MDM4 is a nuclear protein that contains a p53 binding domain at the N-terminus and a RING finger domain at the C-terminus. MDM4 shows structural similarity to p53-binding protein MDM2 and both proteins bind the p53 tumor suppressor protein and inhibit its activity. However, unlike MDM2, MDM4 does not cause nuclear export or degradation of p53. Instead, MDM4 inhibits p53 activity by binding to the transcriptional activation domain of p53. MDM4 is overexpressed in a variety of human cancers (1). Expression level of MDM4 is significantly higher in chronic lymphocytic leukemia. MDM4 is a specific chemotherapeutic target for treating retinoblastoma (2).
DKFZp781B1423; HDMX; MDMX; MGC132766; MRP1
1. Parant, J.et.al: Rescue of embryonic lethality in Mdm4-null mice by loss of Trp53 suggests a nonoverlapping pathway with MDM2 to regulate p53. Nature Genet. 29: 92-95, 2001.
2. Laurie, N. A. et.al: Inactivation of the p53 pathway in retinoblastoma. Nature 444: 61-66, 2006.
Sample Purity Data. For specific information on a given lot, see related technical data sheet.
Storage, Stability and Shipping:
Store product at –70oC. For optimal storage, aliquot target into smaller quantities after centrifugation and store at recommended temperature. For most favorable performance, avoid repeated handling and multiple freeze/thaw cycles.
There are no related publications available for this product.
AKT/PKB Pathway, Apoptosis/Autophagy, Cancer, Cell Cycle, Cellular Stress